Trevena, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Dec 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 2, 2026The maintenance fee for Opioid receptor ligands and methods of using and making same (US 9,044,469) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 1 fee due Jan 18, 2027The maintenance fee for 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same (US 11,702,408) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Compounds and methods of preparing compounds S1P1 modulators (US 11,884,655) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 2 fees due Aug 27, 2027
- 3 fees due Sep 17 to 19, 2027 · next Sep 17
- 1 fee due Oct 12, 2027The maintenance fee for Opioid Receptor Ligands And Methods Of Using And Making Same (US 9,309,234) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,993,511 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,835,488 | Opioid receptor ligands and methods of using and making same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,642,842 | Opioid receptor ligands and methods of using and making same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,849,119 | Opioid receptor ligands and methods of using and making same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,588,898 | Opioid receptor ligands and methods of using and making same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,077,098 | Opioid receptor ligands and methods of using and making same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,931,350 | Opioid receptor ligands and methods of using and making same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,044,469 | Opioid receptor ligands and methods of using and making same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,309,234 | Opioid Receptor Ligands And Methods Of Using And Making Same In force · Low confidence | In force | Low confidence | |
| US 9,518,086 | Crystalline and amorphous forms of a β-arrestin effector In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 20: 6 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 3 abandoned · 8 no status recorded